Araştırma Çıktıları

Permanent URI for this communityhttps://hdl.handle.net/11443/931

Browse

Author: search.filters.author.Kaymaz, Buse

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Annexin A1 as a potential prognostic biomarker for COVID-19 disease: Case-control study
    (WILEY-HINDAWI, 2020-01-01) Canacik, Omer; Sabirli, Ramazan; Altintas, Emel; Karsli, Emre; Karis, Denizhan; Kaymaz, Buse; Sabirli, Gizem Tukenmez; Kurt, Ozgur; Koseler, Aylin
    Background Annexin A1 (AnxA1) is an important endogenous glucocoticoid protein that contributes to the suppression of inflammation by limiting the production of neutrophil and pro-inflammatory cytokines. This study aims to determine the clinical predictivity value of blood AnxA1 levels in patients with mild and severe-critical pneumonia induced by COVID-19. Methods This study employed a prospective, case-control study design and was conducted at Ankara Training and Research hospital between 10 February 2021 and 15 March 2021. A total of 74 patients (42 of whom had moderate and 32 of whom had severe/critical cases of COVID-19 disease according to World Health Organization guidelines) and 50 nonsymptomatic healthy volunteers participated in the study. Blood samples were taken from patients at the time of hospital admission, after which serum was isolated. Following the isolation of serum, AnxA1 levels were evaluated using the enzyme-linked immunosorbent assay method. Results The serum AnxA1 levels were measured as 25.5 (18.6-38.6) ng/ml in the control group, 21.2 (14.7-32) ng/ml in the moderate disease group, and 14.8 (9.7-26.8) ng/ml in the severe/critical disease group. Serum AnxA1 levels were significantly lower in the severe/critical disease group compared with the control and moderate disease groups (P = .01 and P = .0001, respectively). Using receiver operating characteristic analysis, a larger area under the curve (AUC) for the serum AnxA1 levels of the control group (AUC = 0.715, 95\% CI = 0.626-0.803
  • No Thumbnail Available
    Item
    Gaiectin-3 as a Potential Prognostic Biomarker for COVID-19 Disease: A Case-Control Study
    (CUREUS INC, 2022-01-01) Karsli, Emre; Metin, Damla Anabarli; Canacik, Omer; Sabirli, Ramazan; Kaymaz, Buse; Kurt, Ozgur; Koseler, Aylin
    Background Recent studies have investigated the importance of Galetin-3 in inflammation, fibrosis, cell proliferation, cardiac disease, diabetes, and tumor formation. Aims This study aims to investigate the role of the Galectin-3 level in the diagnosis of COVID-19 pneumonia and the value of the Galectin-3 level in predicting the clinical course of the patient. Methods This study employed a prospective, case-control study design and was conducted at Bakircay University Cigli Training and Research Hospital. A total of 100 patients (40 had moderate and 60 had severe/critical COVID-19 disease according to World Health Organisation guidelines) and 50 non-symptomatic healthy volunteers participated in the study. Blood samples were taken from patients at the time of hospital admission, after which serum was isolated. Following the isolation of serum, Galectin-3 levels were evaluated using the enzyme-linked immunosorbent assay (ELISA) method. Results The serum Galectin-3 level was measured as 13.57 (10.9-16.4) ng/mL in the control group, 13.52 (10.69-16.6) ng/mL in the moderate disease group, and 11.65 (6.09-14.33) ng/mL in the severe/critical disease group. Serum Galectin-3 levels were significantly lower in the severe/critical disease group compared to the control and moderate disease groups (p=0.001 and p=0.019, respectively). Using ROC analysis, a larger area under the curve (AUC) for the serum Galectin-3 levels of the control group (AUC-0.622, 95\% CI =0.529-0.714
  • Thumbnail Image
    Item
    Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: A case-control study
    (PERGAMON-ELSEVIER SCIENCE LTD, 2021-01-01) Karsli, Emre; Sabirli, Ramazan; Altintas, Emel; Canacik, Omer; Sabirli, Gizem Tukenmez; Kaymaz, Buse; Kurt, Ozgur; Koseler, Aylin
    Introduction: To our knowledge, the diagnostic value of the sP-Selectin level in the diagnosis of COVID-19 disease has not yet been investigated. In this study, we aimed to assess this by evaluating the relationship between sPSelectin level and the clinical severity of COVID-19 infections. Methods: A total of 80 patients (50 with mild to moderate and 30 with severe COVID-19 pneumonia), and 60 nonsymptomatic healthy volunteers participated in the study. Following serum isolation, sP-Selectin levels were assessed by Enzyme-Linked Immunosorbent Assay (ELISA) method. Results: The serum sP-Selectin level was 1.7 ng/ml in the control group (1-3.78)